Celldex Therapeutics reported Wednesday that its experimental medicine for a condition that causes chronic hives reduced hive activity in patients, completely clearing it in some.
However, there was a high rate of patient discontinuations in the trial, due in part to side effects including changes in hair color. Those concerns sent Celldex shares down more than 20% following the company’s announcement.
https://www.statnews.com/2024/09/25/chronic-hives-celldex-therapeutics-phase-2-trial-barzolvolimab/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.